Neurotensin Receptor 1 (NTSR1) Overexpression in Breast Carcinomas Is Common and Independent of ER/PR/Her2 Expression

Xianyong Gui, Shuhong Liu, Ziran Meng, Zu-Hua Gao

Calgary Laboratory Services, Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada.
Calgary Laboratory Services, Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada;.
Department of Pathology, McGill University, Montreal, Canada.

DOI: 10.4236/jct.2013.47A003                

Abstract

Neurotensin (NT) is a 13-amino acid peptide with trophic effects on some neoplasms. Its bioactivities are mainly mediated by neurotensin receptor 1 (NTSR1). Both NT and NTSR1 were found to be upregulated in breast cancer. NT/NTSR1 thus becomes a potential therapeutic target. We studied whether any correlation exists between the expression of NTSR1 in breast carcinomas and the expression of ER, PR, and Her2. A total 85 cases of invasive ductal (62) and lobular (23) breast carcinomas were studied. Based on their ER/PR profiles, the ductal carcinomas (DCs) were subcategorized into ER+/PR+ (21), ER+/PR﹣ (20), and ER﹣/PR﹣ (21). All of the lobular carcinomas (LCs) were ER+/PR+. 21.57% of all DCs and 5.56% of LCs were Her2 positive. 77.78% of ER﹣/PR﹣ DCs were also Her2 negative (triple negative). The expression of NTSR1 was detected by immunohistochemistry and was semiquantitated (as negative, 1+, 2+, 3+). Both 2+ and 3+ were collectively defined as overexpression. The expression of NTSR1 was weak and focal in non-neoplastic mammary epithelial cells. It is increased in 74.19% of DCs (80.95% in ER+/PR+, 75% in ER+/PR﹣, and 66.67% in ER﹣/PR﹣ group), and in 95.65% of LCs. The overexpression of NTSR1 is similar between ER+ DCs and ER﹣ DCs (75% vs 66.67%, p > 0.05) as well as between PR+ DCs and PR﹣ DCs (80.95% in ER+/PR+ DCs vs 75% in ER+/PR﹣ DCs, p > 0.05). And it was seen in 77.78% of Her2+ DCs, 78.38% of Her2﹣ DCs, 94.12% of Her2﹣ LCs, and 78.57% of triple negative DCs. Overall, NTSR1 is commonly overexpressed in both ductal and lobular breast carcinomas and is independent of the ER/PR/Her2 profiles of the tumors. The present data supports the potential benefit of developing NTSR1 blockers in the adjuvant therapy of breast carcinomas, particularly for those “triple negative” tumors.

Keywords

Neurotensin; Neurotensin Receptor; NTSR1; Breast Carcinoma; Estrogen Receptor; Progesterone Receptor; Her2

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	R. Carraway and S. E. Leeman, “The Isolation of a New Hypotensive Peptide, Neurotensin, from Bovine Hypothalami,” The Journal of Biological Chemistry, Vol. 248, No. 19, 1973, pp. 6854-6861.
[2]	R. Carraway and S. E. Leeman, “Characterization of Radioimmunoassayable Neurotensin in the Rat. Its Differential Distribution in the Central Nervous System, Small Intestine, and Stomach,” The Journal of Biological Chemistry, Vol. 251, No. 22, 1976, pp. 7045-7052.
[3]	C. F. Ferris, M. J. Armstrong, J. K. George, C. A. Stevens, R. E. Carraway and S. E. Leeman, “Alcohol and Fatty Acid Stimulation of Neurotensin Release from Rat Small Intestine,” Endocrinology, Vol. 116, No. 3, 1985, pp. 1133-1138. doi:10.1210/endo-116-3-1133
[4]	B. M. Evers, “Neurotensin and Growth of Normal and Neoplastic Tissues,” Peptides, Vol. 27, No. 10, 2006, pp. 2424-2433. doi:10.1016/j.peptides.2006.01.028
[5]	F. Souaze, S. Dupouy, V. Viardot-Foucault, E. Bruyneel, S. Attoub, C. Gespach, et al., “Expression of Neurotensin and NT1 Receptor in Human Breast Cancer: A Potential Role in Tumor Progression,” Cancer Research, Vol. 66, No. 12, 2006, pp. 6243-6249. doi:10.1158/0008-5472.CAN-06-0450
[6]	S. Somai, A. Gompel, W. Rostene and P. Forgez, “Neurotensin Counteracts Apoptosis in Breast Cancer Cells,” Biochemical and Biophysical Research Communications, Vol. 295, No. 2, 2002, pp. 482-488. doi:10.1016/S0006-291X(02)00703-9
[7]	S. Dupouy, V. Viardot-Foucault, M. Alifano, F. Souaze, G. Plu-Bureau, M. Chaouat, et al., “The Neurotensin Receptor-1 Pathway Contributes to Human Ductal Breast Cancer Progression,” PloS One, Vol. 4, No. 1, 2009, Article ID: e4223.
[8]	Y. Heakal and M. Kester, “Nanoliposomal Short-Chain Ceramide Inhibits Agonist-Dependent Translocation of Neurotensin Receptor 1 to Structured Membrane Microdomains in Breast Cancer Cells,” Molecular Cancer Research, Vol. 7, No. 5, 2009, pp. 724-734. doi:10.1158/1541-7786.MCR-08-0322
[9]	D. Gully, B. Labeeuw, R. Boigegrain, F. Oury-Donat, A. Bachy, M. Poncelet, et al., “Biochemical and Pharmacological Activities of SR 142948A, a New Potent Neurotensin Receptor Antagonist,” Journal of Pharmacology and Experimental Therapeutics, Vol. 280, No. 2, 1997, pp. 802-812.
[10]	D. Zhao, Y. Zhan, H. Zeng, H. W. Koon, M. P. Moyer and C. Pothoulakis, “Neurotensin Stimulates Expression of Early Growth Response Gene-1 and EGF Receptor through MAP Kinase Activation in Human Colonic Epithelial Cells,” International Journal of Cancer, Vol. 120, No. 8, 2007, pp. 1652-1656. doi:10.1002/ijc.22407
[11]	D. Zhao, Y. Zhan, H. W. Koon, H. Zeng, S. Keates, M. P. Moyer and C. Pothoulakis, “Metalloproteinase-Dependent Transforming Growth Factor-Alpha Release Mediates Neurotensin-Stimulated MAP Kinase Activation in Human Colonic Epithelial Cells,” The Journal of Biological Chemistry, Vol. 279, No. 42, 2004, pp. 43547-43554. doi:10.1074/jbc.M401453200
[12]	S. Hassan, P. R. Dobner and R. E. Carraway, “Involvement of MAP-Kinase, PI3-Kinase and EGF-Receptor in the Stimulatory Effect of Neurotensin on DNA Synthesis in PC3 Cells,” Regulatory Peptides, Vol. 120, No. 1-3, 2004, pp. 155-166. doi:10.1016/j.regpep.2004.03.004
[13]	M. J. Alexander and S. E. Leeman, “Estrogen-Inducible Neurotensin Immunoreactivity in the Preoptic Area of the Female Rat,” Journal of Comparative Neurology, Vol. 345, No. 4, 1994, pp. 496-509. doi:10.1002/cne.903450403
[14]	J. J. Watters and D. M. Dorsa, “Transcriptional Effects of Estrogen on Neuronal Neurotensin Gene Expression Involve cAMP/Protein Kinase A-Dependent Signaling Mechanisms,” The Journal of Neuroscience, Vol. 18, No. 17, 1998, pp. 6672-6680.
[15]	W. H. Rostene and M. J. Alexander, “Neurotensin and Neuroendocrine Regulation,” Frontiers in Neuroendocrinology, Vol. 18, No. 2, 1997, pp. 115-173. doi:10.1006/frne.1996.0146
[16]	M. J. Alexander, “Colocalization of Neurotensin Messenger Ribonucleic Acid (mRNA) and Progesterone Receptor mRNA in Rat Arcuate Neurons under Estrogen-Stimulated Conditions,” Endocrinology, Vol. 140, No. 11, 1999, pp. 4995-5003. doi:10.1210/en.140.11.4995
[17]	P. Taneja, D. Maglic, F. Kai, S. Zhu, R. D. Kendig, E. A. Fry and K. Inoue, “Classical and Novel Prognostic Markers for Breast Cancer and Their Clinical Significance,” Clinical Medicine Insights: Oncology, Vol. 4, 2010, pp. 15-34.
[18]	K. Iwase, B. M. Evers, M. R. Hellmich, H. J. Kim, S. Higashide, D. Gully, et al., “Indirect Inhibitory Effect of a Neurotensin Receptor on Human Colon Cancer (LoVo) Growth,” Surgical Oncology, Vol. 5, No. 5-6, 1996, 245-251. doi:10.1016/S0960-7404(96)80028-4
[19]	T. W. Moody, J. Chiles, M. Gasibang, E. Moody, D. Chan and T. P. Davis, “SR48692 Is a Neurotensin Receptor Antagonist Which Inhibits the Growth of Small Cell Lung Cancer Cells,” Peptides, Vol. 22, No. 1, 2001, pp. 109-115. doi:10.1016/S0196-9781(00)00362-4
[20]	R. Castillo-Rodriguez, A. Arango-Rodriguez, L. Escobedo, H. Rubio-Zapata, V. Tellez-Lopez, T. Mejia-Castillo, et al., “Neurotensin-Polyplex as a Potential Tool in Gene Therapy for Human Breast Cancer,” European Journal of Cancer, Vol. 48, Suppl. 1, 2012, p. S93. doi:10.1016/S0959-8049(12)70252-6
[21]	J. F. White, N. Noinaj, Y. Shibata, J. Love, B. Kloss, F. Xu, et al., “Structure of the Agonist-Bound Neurotensin Receptor,” Nature, Vol. 490, No. 7421, 2012, pp. 508-513. doi:10.1038/nature11558